Your SlideShare is downloading. ×
SHARE: Report Back from SABCS Focusing on Metastatic Breast Cancer
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

SHARE: Report Back from SABCS Focusing on Metastatic Breast Cancer

950
views

Published on

Stephen C. Malamud, MD, Department of Medicine, Beth Israel Medical Center, presented at SHARE on the latest news from the San Antonio Breast Cancer Symposium (SABCS) 2013 as it relates to metastatic …

Stephen C. Malamud, MD, Department of Medicine, Beth Israel Medical Center, presented at SHARE on the latest news from the San Antonio Breast Cancer Symposium (SABCS) 2013 as it relates to metastatic disease. If you'd like to view the complete webinar, go to www.sharecancersupport.org/malamud

The information in this presentation is not intended to be a substitute for professional medical advice, diagnosis or treatment. The presentation was given on February 20, 2014.

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
950
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
9
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. San Antonio Breast Cancer Symposium- 2013 The Future of Metastatic Breast Cancer Stephen C. Malamud MD Medical Oncology Beth Israel Medical Center-Comprehensive Cancer Center
  • 2. Breast Cancer: Surgery for Stage IV ?
  • 3. Tata Memorial Study Tata Memorial (India)- 350 patients from 2005-2012 Endpoint- overall survival Projected benefit: median survival- increase in survival from 18 to 24 months Initial therapy in experimental arm- CAF+/- T Stratifications: number and type of metastases, ER status, age, menopause Subset analysis: age, ER status, HER2 status, number and type of metastases
  • 4.  Study size: 271 (2008-12)  Endpoint: overall survival  Initial therapy: primary site local therapy  Stratification: none described  Inclusion of radiotherapy: yes  Subset analysis planned: age, ER/Her2/triple negative, one organ site; bone only; all other solitary bone lesions; multiple bone lesions Turkish Study:
  • 5. Tata Memorial Study:
  • 6.  Turkey: both groups median age 52  Tata Memorial: 47 and 48  Turkey: tumor size- more T2 and T4 tumors in ST arm; grade similar between 2 arms  Tata Memorial: tumor size: not described; grade not described  Both studies: Lymph node involvement not described  Tata Memorial: ER+: 51% and 49%  Turkey- fewer ER+ and more Triple Negative patients on the ST arm  Metastatic burden: Tata- balanced for >3 lesions, Turkey- single organ site more frequent in surgical arm  Bone only metastases- Tata- balanced between arms; Turkey- fewer in ST arm, non-bone metastases more frequent in ST arm Study characteristics: Comparative Analysis